Lexicon Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations

Lexicon Pharmaceuticals (NASDAQ:LXRX) First Quarter 2025 Results

Key Financial Results

• Revenue: US$1.26m (up 12% from 1Q 2024).
• Net loss: US$25.3m (loss narrowed by 48% from 1Q 2024).
• US$0.07 loss per share (improved from US$0.20 loss in 1Q 2024).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Lexicon Pharmaceuticals Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 6.6%. Earnings per share (EPS) also surpassed analyst estimates by 32%.

Looking ahead, revenue is forecast to grow 39% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 22% from a week ago.

Risk Analysis

We don't want to rain on the parade too much, but we did also find 3 warning signs for Lexicon Pharmaceuticals (2 are potentially serious!) that you need to be mindful of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.